Retail Crowd Joins Short Sellers at HRMY's Door

Eight days before Harmony Biosciences reports earnings, two very different groups are paying close attention. Short sellers have spent the past week adding positions. Now retail investors are piling in too, with Wikipedia and ORTEX page-view data showing attention 7.2 standard deviations above its own 90-day average.

The divergence makes HRMY one of the more charged set-ups in small-cap pharma right now.

Retail Attention Spikes

The retail attention reading of 7.2 standard deviations, measured by ORTEX Alt Data from English Wikipedia article views and distinct ORTEX stock page visitors, is the sharpest signal in this snapshot. This is a measure of attention, not a revenue or earnings indicator. But attention at this level, this close to an event, tells you the stock is on a lot of screens.

Harmony's next earnings report is October 27. That is eight days away.

Short Sellers Still Adding, Cheaply

The short interest update published today extends the picture from yesterday's note. SI has reached 9.7% of free float, up 17.4% over the past week. The pace of accumulation is notable. What is equally notable is the cost: borrow sits at just 0.21%, down 51% on the week, the lowest level in at least a month.

Availability remains ample at 649%. For context, the 52-week tightest reading was 591%. Shorts are not being squeezed out or squeezed in. They are adding at will, at near-zero carry cost. That reads as a considered pre-earnings directional trade, not distressed covering or forced entry.

Analysts Hold Their Ground

Against the short positioning, the analyst consensus stays at buy, with a mean price target of $48.25. The stock closed at $37.95 on Friday, down 5.8% on the week. HC Wainwright and Needham both reiterated Buy ratings this week with targets of $55 and $50 respectively. That is 27% to 45% above Friday's close.

The bull case rests on WAKIX's commercial momentum: 2026 net revenue guidance of $1.00 billion to $1.04 billion, 450 net patient additions in the second quarter and 8,950 patients on treatment. The bear case centres on concentration risk. WAKIX is the revenue engine, and any slowdown in new patient adds or fresh competition in the sodium oxybate market would directly hit the top line.

BlackRock added 539,195 shares in the quarter to September 30, lifting its stake to 12.2%. American Century added 486,139 shares over the same period. Both moves were disclosed after quarter-end and represent the most recent institutional flow data available.

Medicaid Reimbursement Trend

CMS Medicaid drug utilisation data, published by the Centers for Medicare and Medicaid Services, shows Medicaid dollars reimbursed for the relevant drug rising for four consecutive quarters, with the most recent quarter up 20% on the same period a year earlier at $38.7 million. This series has not been shown to lead Harmony's reported financials, so it is context rather than a forward signal. It does confirm the drug's government payer penetration is still expanding.

What to watch: Whether retail attention converts into volume in the days before October 27, and whether short sellers cover ahead of the print or hold into it. The borrow market is giving them no reason to rush either way.